AMRI Signs Agreement with AstraZeneca for COVID-19 Vaccine Delivery
AMRI will provide AstraZeneca with manufacturing capacity and sterile fill/finish services at its drug product manufacturing facility in Albuquerque, NM.
AMRI, a provider of drug development and manufacturing solutions, announced on Sept. 3, 2020 that it signed a supply agreement with AstraZeneca to support the manufacture of AstraZeneca’s COVID-19 vaccine candidate, AZD1222.
According to an AMRI press release, AMRI will provide AstraZeneca with manufacturing capacity and sterile fill/finish services at its drug product manufacturing facility in Albuquerque, NM.
“AMRI is proud to partner with AstraZeneca in pursuit of a vaccine that could protect people against the coronavirus pandemic,” said John Ratliff, CEO, AMRI, in the press release. “Our experience in drug product fill/finish will enable timely manufacturing to make the vaccine available as soon as possible to advance bringing life-changing medicines to market.”
On Sept. 9, 2020, AstraZeneca announced that all ongoing randomized, controlled clinical trials involving AZD1222 will temporarily pause due to a patient’s unexplained illness in the vaccine’s Phase III trial in the United Kingdom, an AstraZeneca press release said. Currently, AstraZeneca is independently reviewing the incident.
Sources: AMRI, AstraZeneca
Telix Enters Agreement with ImaginAb to Purchase Next-Gen Therapeutic Candidates
Published: January 13th 2025 | Updated: January 13th 2025The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
